Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials

0 avis

Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials

Archive ouverte

Edité par CCSD ; Elsevier -

International audience

Langue: en

Consulter en ligne

Consulter le document

Suggestions

Du même auteur

MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency

Archive ouverte | Clément, Karine | CCSD

International audience

A Melanocortin-4 Receptor Agonist Induces Skin and Hair Pigmentation in Patients with Monogenic Mutations in the Leptin-Melanocortin Pathway

Archive ouverte | Kanti, Varvara | CCSD

International audience. Background and Objectives: Gene mutations within the leptin-melanocortin signaling pathway lead to severe early-onset obesity. Recently, a phase 2 trial evaluated new pharmacological treatmen...

Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency

Archive ouverte | Kühnen, Peter | CCSD

International audience. Introduction: Individuals with proopiomelanocortin (POMC) or leptin receptor (LEPR) deficiency are young and experience severe obesity, hyperphagia, and comorbidities, which can impair qualit...

Chargement des enrichissements...